Welcome to Traders.com Advantage!

TECHNICAL ANALYSIS  |  May 8, 2020
Untidy Charts
Remdesivir is an antiviral medication developed by Gilead. The Federal Drug Administration recently authorized its use in COVID-19 patients because research has shown that it shortened recovery times in people seriously ill from the coronavirus. News of the clinical trials was already out weeks earlier and the trading in the company's stock reflected that. Trading behavior caused what I call an untidy chart to form.
by Stella Osoba, CMT

You must be a registered member of STOCKS & COMMODITIES magazine to read the article you’ve requested.

Simply fill in your name and address and submit this form to us to receive your FREE TRIAL subscription to STOCKS & COMMODITIES.

This will begin your trial subscription at the special introductory rate of only $89.99 for 1 year. You will receive a trial issue of the magazine in the mail and also be able to access a sample digital issue of the magazine online in our subscriber area. In addition, you will have access to our online publications Working Money and Traders.com Advantage for 30 days!. Your log-in information will also be provided via the Email address you submit with the form below.

If you are not satisfied with your sample issue of Stocks & Commodities magazine, just return your bill marked “cancel” and owe nothing. The sample issue is yours to keep!

HELPQuestions or Comments? Send message to: Circ@Traders.com